

PROVIDER QUICK POINTS

PROVIDER INFORMATION



March 8, 2023

Commercial Pharmacy Benefit Exclusion for Cinryze®, Kalbitor®, Leqembi™, and Nexobrid®

Effective **March 8, 2023**, the drugs listed in the table below will be excluded from pharmacy benefit coverage due to clinician-administered route of administration and may be available for medical benefit coverage for subscribers who are eligible.

| Drug Name |
|---|
| Cinryze® (human c1-esterase inhibitor) solution for intravenous (IV) infusion |
| Kalbitor® (ecallantide) solution for subcutaneous (SQ) injection |
| Leqembi™ (lecanemab-irmb) solution for intravenous (IV) infusion |
| Nexobrid® (anacaulase-bcdb) topical gel |

Products Impacted

This applies to the commercial line of business.

Questions?

Please contact provider services at **(651) 662-5200** or **1-800-262-0820**.